LUNG Pulmonx Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: LUNG

Price (delayed)

$2

Market cap

$85.9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.16

Enterprise value

$86.01M

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 84
Relative Valuation: Rel. Valuation: 27
Relative Profitability: Rel. Profitability: 29

Pulmonx ® Corporation is a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD. The Pulmonx solution, which is comprised of ...

Highlights
Pulmonx's EPS has increased by 19% YoY and by 11% from the previous quarter
The net income has grown by 15% YoY and by 10% from the previous quarter
The company's equity fell by 43% YoY and by 14% QoQ
The quick ratio is down by 25% year-on-year and by 13% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://pulmonx.com
Peers: OFIX

Key stats

What are the main financial stats of LUNG

LUNG stock price

How has the Pulmonx stock price performed over time
Intraday
-2.91%
1 week
2.56%
1 month
-11.5%
1 year
9.89%
YTD
-9.5%
QTD
53.85%

Financial performance

How have Pulmonx's revenue and profit performed over time
Revenue
$87.44M
Gross profit
$67.38M
Operating income
-$46.31M
Net income
-$48.12M
Gross margin
77.1%
Net margin
-55%
The operating income rose by 19% year-on-year and by 11% since the previous quarter
Pulmonx's operating margin has increased by 16% YoY and by 10% from the previous quarter
The net income has grown by 15% YoY and by 10% from the previous quarter
Pulmonx's net margin has increased by 13% YoY and by 8% QoQ

Price vs fundamentals

How does LUNG's price correlate with its fundamentals

Growth

What is Pulmonx's growth rate over time

Valuation

What is Pulmonx stock price valuation
P/E
N/A
P/B
2.16
P/S
0.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.98
Pulmonx's EPS has increased by 19% YoY and by 11% from the previous quarter
The P/B is 71% higher than the last 4 quarters average of 1.3 but 31% lower than the 5-year quarterly average of 3.2
The company's equity fell by 43% YoY and by 14% QoQ
The price to sales (P/S) is 87% less than the 5-year quarterly average of 7.6 but 43% more than the last 4 quarters average of 0.7
The revenue has contracted by 3.4% YoY

Efficiency

How efficient is Pulmonx business performance
The company's return on equity fell by 39% YoY and by 4.1% QoQ
Pulmonx's ROS has increased by 15% YoY and by 10% from the previous quarter
LUNG's return on invested capital is up by 8% since the previous quarter but it is down by 4.2% year-on-year
The ROA fell by 6% YoY but it rose by 3.8% QoQ

Dividends

What is LUNG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LUNG.

Financial health

How did Pulmonx financials performed over time
Pulmonx's total assets is 52% more than its total liabilities
The quick ratio is down by 25% year-on-year and by 13% since the previous quarter
Pulmonx's total assets has decreased by 22% YoY and by 4.4% from the previous quarter
Pulmonx's debt is 43% higher than its equity
The debt to equity has surged by 74% year-on-year and by 16% since the previous quarter
The company's equity fell by 43% YoY and by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.